Tomas Smutny

Tomas Smutny

Auto-generated profile, based on publicly available information

Tomas Smutny

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GKGalina Karabanovich
Galina Karabanovich
JZJúlia Zemanová
Júlia Zemanová
TSTomáš Smutný
Tomáš Smutný
RSRita Székely
Rita Székely
MŠMichal Šarkan
Michal Šarkan
JRJaroslav Roh
Jaroslav Roh

1 October 2016 in Biomaterials
Verified
Journal Article
Open access
LKLiisa K. Kanninen
Liisa K. Kanninen
RHRiina Harjumäki
Riina Harjumäki
PPPasi Peltoniemi
Pasi Peltoniemi
MBMariia S. Bogacheva
Mariia S. Bogacheva
TSTuuli Salmi
Tuuli Salmi
Yan-Ru LouYan-Ru Lou
Yan-Ru Lou
Human pluripotent stem cells (hPSCs) have gained a solid foothold in basic research and drug industry as they can be used in vitro to study human development and have potential to offer limitless supply of various somatic cell types needed in drug development. Although the hepatic differentiation of hPSCs has been extensively studied, only a little attention has been paid to the role of the extracellular matrix. In this study we used laminin-511, laminin-521, and fibronectin, found in human liver progenitor cells, as culture matrices for hPSC-derived definitive endoderm cells. We observed that laminin-511 and laminin-521 either alone or in combination support the hepatic specification and that fibronectin is not a vital matrix protein for the hPSC-derived definitive endoderm cells. The expression of the laminin-511/521-specific integrins increased during the definitive endoderm induction and hepatic specification. The hepatic cells differentiated on laminin matrices showed the upregulation of liver-specific markers both at mRNA and protein levels, secreted human albumin, stored glycogen, and exhibited cytochrome P450 enzyme activity and inducibility. Altogether, we found that laminin-511 and laminin-521 can be used as stage-specific matrices to guide the hepatic specification of hPSC-derived definitive endoderm cells.

1 July 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GKGalina Karabanovich
Galina Karabanovich
JRJaroslav Roh
Jaroslav Roh
TSTomáš Smutný
Tomáš Smutný
JNJan Němeček
Jan Němeček
PVPetr Vicherek
Petr Vicherek
AHAlexandr Hrabálek
Alexandr Hrabálek

1 March 2015 in Toxicology Letters
Verified
Journal Article
Closed access
ACAlejandro Carazo
Alejandro Carazo
TSTomas Smutny
Tomas Smutny
LHLucie Hyrsová
Lucie Hyrsová
KBKarel Berka
Karel Berka
PPPetr Pavek
Petr Pavek

10 September 2013 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
PDF file
PPPetr Pavek
Petr Pavek
TSTomas Smutny
Tomas Smutny
Over the past 20 years, the toxicological and protective roles of the placental barrier with respect to drug detoxification and transporter-controlled protection of the fetus have been intensively examined. Several cytochrome P450 enzymes are expressed in placental trophoblast at different stages of pregnancy, though only a few of these have functional activity to metabolize xenobiotics. Drug transporters such as P-glycoprotein/MDR1 or breast cancer resistance protein (BCRP) are highly expressed in the placenta, and their functional activities have been demonstrated in the placenta both in vitro and in vivo. In addition, several studies have reported on ligand-activated transcription factors and nuclear receptors referred to as “xenosensors” in the placenta. The xenosensors control transcriptional regulation of both xenobiotic-metabolizing enzymes and drug transporters in different organs. Their ligands include toxic compounds and environmental pollutants, drugs, as well as herbal, dietary or vitamin supplements. Nevertheless, it remains debatable whether the placental barrier adapts to toxic injuries coming either from maternal medication or environmental contamination and whether the placenta contains a mechanism to respond dynamically in protecting the developing fetus. In the present paper, we summarize current knowledge about the activity and expression of major ligand-activated transcriptional mechanisms involved in biotransformation enzymes and transporters regulation in human placenta. In particular, we highlight the emerging roles of aryl hydrocarbon (AHR), vitamin D (VDR), glucocorticoid (GR) and pregnane X (PXR) receptors in that regulation. We show that the placenta constitute a unique metabolizing organ with significant overlap of exogenous and endogenous compounds metabolism controlled by nuclear receptors.

8 April 2016 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
LHLucie Hyrsova
Lucie Hyrsova
TSTomas Smutny
Tomas Smutny
ACAlejandro Carazo
Alejandro Carazo
SMStefan Moravcik
Stefan Moravcik
JMJana Mandikova
Jana Mandikova
PPPetr Pavek
Petr Pavek